Document Coversheet  
 
 Study Title:     A Phase II Multicenter, Single Arm, Open- Label Trial to Evaluate the Efficacy and 
Safety of Denosumab in Treatment of Post -Allogenic Hematopoietic Stem Cell Transplant Bone 
Loss  
 
 
 
Institution/Site:  Roswell Park Comprehensive Cancer Center  
Document (Approval/Update) Date:  09/0 9/2021  
Study ID: [REMOVED]  
IRB Number  I [ZIP_CODE]  
 
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 1 of 36 07/20/21  
   
 
PROTOCOL TITLE:  
A Phase II Multicenter, Single Arm, Open -Label Trial to Evaluate the Efficacy and Safety 
of Denosumab in Treatment of Post -Allogenic Hematopoietic Stem Cell Transplant Bone 
Loss  
PROTOCOL NUMBER:  
I [ZIP_CODE]  
PRINCIPAL INVESTIGATOR:  
[CONTACT_47310] L. McCarthy  
Roswell Park Comprehensive Cancer Center  
Elm and Carlton Street  
Buffalo, [LOCATION_001] [ZIP_CODE]  
[PHONE_8353]  
[EMAIL_7724]  
VERSION NUMBER:  
5 
DATE:  
20 July  2021 
Confidentiality Statement  
Any and all information presented in this document shall be treated as confidential and shall 
remain the exclusive property of the party (ies) mentioned above (Roswell Park Cancer Institute 
Corporation d/b/a Roswell Park Compreh ensive Cancer Institute) . The use of such confidential 
information must be restricted to the recipi[INVESTIGATOR_225195], 
published, or otherwise communicated to any unauthorized persons, for any reason, in any form 
whatsoeve r without the prior written consent of the party(ies) above .
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 2 of 36 07/20/21  
  Table of Contents  
1. Objectives ................................ ................................ ................................ ........................  5 
1.1 Primary Objective  ................................ ................................ ................................ .........  5 
2 Background  ................................ ................................ ................................ .....................  5 
2.1 Bone Health in Hematopoietic Stem Cell Transplant  ................................ ......................  5 
2.2 Denosumab  ................................ ................................ ................................ ...................  5 
2.2.1  Mechanism of Action ................................ ................................ ................................ . 6 
2.2.2  Preclinical Pharmacology and Pharmacokinetics  ................................ .........................  6 
2.2.3  Toxicology/ Interactions  ................................ ................................ ............................  [ADDRESS_509532] Cancer ................................ ...............  7 
2.4 Rationale ................................ ................................ ................................ .......................  8 
3 Inclusion and Exclusion Criteria  ................................ ................................ .......................  8 
3.1 Inclusion Criteria ................................ ................................ ................................ ...........  8 
3.2 Exclusio n Criteria  ................................ ................................ ................................ .........  8 
3.3 Special Populations  ................................ ................................ ................................ ....... 9 
3.4 Inclusion of Women and Minorities  ................................ ................................ ...............  9 
4 Local and Study -Wide Number of Subjects ................................ ................................ ....... 9 
5 Local and Study -Wide Recruitment Methods  ................................ ................................ .... 9 
6 Multi -Site Research ................................ ................................ ................................ ..........  9 
7 Study Timelines  ................................ ................................ ................................ .............  10 
8 Study Endpoint s................................ ................................ ................................ .............  10 
8.1 Primary Endpoint(s)  ................................ ................................ ................................ .... [ADDRESS_509533]  ................................ ................................ ................................ ... 14 
16.1  Bone Density Status  ................................ ................................ ................................ .... 14 
16.2  Other Response Parameters  ................................ ................................ .........................  14 
17 Safety Evaluation  ................................ ................................ ................................ ...........  14 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 3 of 36 07/20/21  
  17.1  Adverse Events  ................................ ................................ ................................ ...........  14 
17.1.1  Diagnosis Versus Signs and Symptoms  ................................ ................................ .... 15 
17.1.2  Adverse Events Occurring Secondary to Other Events  ................................ ..............  15 
17.1.3  Abnormal Laboratory Values  ................................ ................................ ...................  15 
17.1.4  Preexisting Medical Conditions (Baseline Conditions)  ................................ ..............  15 
17.2  Grading and Reporting Adverse Events ................................ ................................ ........  16 
17.2.1  Grading and Relationship to Drug  ................................ ................................ ............  16 
17.3  Reporting Adverse Events  ................................ ................................ ...........................  16 
17.4  Serious Adverse Events  ................................ ................................ ...............................  16 
17.4.1  Reporting Serious Adverse Events ................................ ................................ ............  17 
17.5  Investigator Reporting: Notifying the Study Sponsor  ................................ ....................  17 
17.6  Follow -Up for Serious Adverse Events  ................................ ................................ ........  17 
17.7  Unanticipated Problems ................................ ................................ ...............................  17 
17.7.1  Reporting Unanticipated Problems:  ................................ ................................ ..........  [ADDRESS_509534] the Privacy Interests of Subjects  ................................ .....................  21 
26 Resources Available ................................ ................................ ................................ ....... 21 
27 Prior Approvals ................................ ................................ ................................ ..............  21 
28 Compensation for Research -Related Injury  ................................ ................................ ..... 21 
29 Economic Burden to Subjects  ................................ ................................ .........................  22 
30 Consent Process  ................................ ................................ ................................ .............  22 
31 Process to Document Consent in Writing  ................................ ................................ ........  22 
32 Drugs or Devices  ................................ ................................ ................................ ...........  23 
32.1  Denosumab (Prolia¬Æ) ................................ ................................ ................................ .. 23 
32.2  Active Substance and Source  ................................ ................................ .......................  23 
32.3  Drug Shipment  ................................ ................................ ................................ ............  23 
32.4  Preparati on for Administration ................................ ................................ .....................  23 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 4 of 36 07/20/21  
  32.5  Storage and Stability  ................................ ................................ ................................ ... 23 
33 References  ................................ ................................ ................................ .....................  24 
34 Appendices  ................................ ................................ ................................ ....................  25 
 
  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 5 of 36 07/20/21  
  1. OBJECTIVES  
1.1 Primary Objective  
‚Ä¢ To evaluate th e efficacy and safety of denosumab therapy for the treatment of bone loss in 
patients who have received an allogeneic hematopoietic stem cell transplant.  
2 BACKGROUND  
2.1 Bone Health in Hematopoietic Stem Cell Transplant  
Allogeneic Hematopoietic Stem Cell Transplant (HSCT) is a curative treatment of hematologic 
malignancies but can have varying effects on quality of life due to complications. 1Amongst 
survivorship monitoring in these patients bone mineral density (BMD) by [CONTACT_751] -energy x -ray 
absorpt iometry (DXA) scan is commonly monitored due to accelerated bone loss from the effects 
of previous chemotherapy, the HSCT, and/or administration of steroids. Previous research has 
shown on average a patient undergoing HSCT can expect to have a decrease in BMD by 3.5% to 
8.5% correlating with [ADDRESS_509535]. 
2Furthermore, accelerated bone loss exponentially increases the risk of a fracture with 10% to 15% 
of bone loss correlated to a doubling of the fracture risk regardless of osteopenia/osteoporosis 
status. This is leadi ng to direct and indirect increases in treatment costs as well as a hindrance to 
the quality of life of post -HSCT patients. [ADDRESS_509536] patients but can be associated with 
adve rse effects, including infusion reactions associated with fevers and flu -like symptoms, which 
can lead to unsubstantiated evaluation and treatment of infection, decreased compliance, and 
even discontinuation. 4Denosumab is a receptor activator of nuclear factor kappa -B ligand 
(RANKL) inhibitor which is also currently approved for treatment of osteoporosis and is less 
likely to be associated with the same injection reactions as zoledronic acid 
(http://www.pi.amgen.com/~/media/amgen/repositorysites/pi -amgen -com/prolia/prolia_pi.ashx ). 
Currently, there has been minimal data produced on the efficacy and safety of  denosumab in 
HSCT patients. To address this lack of published data, Roswell Park and Cleveland Clinic are 
proposing a joint phase [ADDRESS_509537] 
patients.  
2.2 Denosumab  
Denosumab is a fully human monoclon al antibody with high affinity and specificity to RANK 
Ligand (RANKL) leading to decreased activation. Denosumab has high specificity to RANKL 
while being devoid of activity towards other members of the tumor necrosis factor (TNF) family 
including TNFŒ±, TN FŒ≤, TNF -related apoptosis -inducing ligand (TRAIL), or CD40 ligand. Down 
regulation of RANKL caused by [CONTACT_404160],  leading to an increase in bone mass and strength.  
Currently, denosumab  is approved in the [LOCATION_002] (US) for treatment of osteoporosis in 
postmenopausal women as well as men at increased or high risk for fracture, bone loss due to 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 6 of 36 07/20/[ADDRESS_509538] cancer at  
high risk for fracture.  
A detailed discussion of the preclinical pharmacology, pharmacokinetics, and toxicology of 
denosumab can be found in the Investigator‚Äôs Brochure.  
2.2.1 Mechanism of Action  
Denosumab Binds to RANKL, a transmembrane or soluble protein esse ntial for the formation, 
function, and survival of osteoclasts, the cells responsible for bone resorption. Prolia prevents 
RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. 
Prevention of the RANKL/ RANK interacti on inhibits osteoclast formation, function, and survival, 
thereby [CONTACT_404161].  
2.2.2 Preclinical Pharmacology and Pharmacokinetics  
Onset of action : Decreases markers of bo ne resorption by ~85% within 3 days; maximal reduction 
observed within 1 month.  
Duration : Markers of bone resorption return to baseline within 12 months of discontinuing therapy2 
Bioavailability : SubQ: 62% 
Half-life elimination : ~25 to 28 days 
Time to peak : 10 days (range 3 to 21) 
Elimination : Clearance may occur via reticuloendothelial system; renal excretion not expected 
2.2.3 Toxicology/ Interactions  
No preclinical drug -drug interactions were studied using Denosumab.  
In ovariectomized monkeys, once -monthly tre atment with Denosumab suppressed bone turnover 
and increased bone mineral density and strength of cancellous and cortical bone at doses 50 -fold 
higher than the recommended human dose of 60  mg administered once every 6 months, based on 
body weight. Bone tis sue was normal with no evidence of mineralization defects, accumulation of 
osteoid or woven bone.  
Adolescent primates treated with Denosumab at doses >10 times higher than the recommended 
human dose of 60  mg administered once every 6 months, based on mg/ k g, had abnormal growth 
plates, considered to be consistent with the pharmacological activity of Denosumab.  
RANK/ RANKL knockout mice exhibited absence of lymph node formation, as well as an absence 
of lactation due to inhibition of mammary gland maturation . Neonatal RANK/ RANKL knockout 
mice exhibited reduced bone growth and lack of tooth eruption. A corroborative study in 2 -week -
old rats given the RANKL inhibitor also showed reduced bone growth, altered growth plates, and 
impaired tooth eruption.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 7 of 36 07/20/21  
  2.3 Clinical Studies with Denosumab  
2.3.1 Osteoporosis in Postmenopausal Women at High Risk for Fracture  
A 3-year, randomized, double -blind, placebo -controlled trial enrolled postmenopausal women 
with baseline BMD T -scores between -2.5 and -4.0 at either the lumbar spi[INVESTIGATOR_404146] : 
A total of 7808 woman were enrolled with a mean age of 72 years and either received denosumab 
60 mg (n=3902) or placebo (n=3906) every 6 months along with 1000 mg calcium and 400 IU 
vitamin D daily. The primary efficacy variable was incidence of vertebral fracture after 3 years. 
The incidence of new vertebral fractures was clinically significant (P < 0.0001) between the 
placebo group (7.2%) compared to the denosumab group (2.3%) over the 3 -year period. This 
produced an absolute risk reduction of 4.8% and a relative risk reduction of 68%. A secondary 
outcome of the study was incidence of hip fractures which was clinically significant (P=0.04) as 
well between the placebo group (1.2%) compared to the denosumab group (0.7%) after 3 years. 
This produced an absolu te risk reduction of 0.3% and a relative risk reduction of 40%.  
2.3.2 Osteoporosis in Men at High Risk for Fracture  
A 1-year, randomized, double -blind, placebo -controlled trial enrolled men with baseline BMD T -
scores between -2.0 and -3.5 as well as men with pr evious fractures with BMD T -scores between 
-1.0 and -3.5 at the lumbar spi[INVESTIGATOR_404147] : 
A total of 242 men were enrolled with a mean age of 65 years and either received denosumab 60 
mg (n=121) or placebo (n=121) every 6 months along with 1000 mg calc ium and 400 IU vitamin 
D daily. The primary efficacy variable was percentage change in the BMD of the lumbar spi[INVESTIGATOR_050], 
total hip, and femora neck from baseline to 1 year. The treatment differences were 4.8% [(+0.9% 
placebo, +5.7% denosumab (95% CI 4.0, 5.6), p< 0.0001)] at lumbar spi[INVESTIGATOR_050], 2% (+0.3% placebo, 
+2.4% denosumab) at the hip, and 2.2% (0.0% placebo, +2.1% denosumab) at femoral neck.  
2.3.3 Treatment of Bone Loss in Men with Prostate Cancer  
A 3-year, randomized, double -blind, placebo -controlled, multinational  study : 
The trial enrolled men < 70 years of age with baseline BMD T -scores between -1.0 and -4.0 at the 
lumbar spi[INVESTIGATOR_050], total hip or femoral neck, or had a history of osteoporotic fracture. A total of 1468 
men were enrolled with a median age of 76 years (Ra nge: 48 to 97 years) and either received 
denosumab 60 mg (n=734) or placebo (n=734) every 6 months for a total of 6 doses along with 
1000 mg calcium and 400 IU vitamin D daily. The primary efficacy variable was percentage 
change in the BMD of the lumbar sp ine from baseline to 2 years. The treatment differences were 
6.7% ( -1.0% placebo, +5.6% denosumab; (95% CI 6.2, 7.1); p< 0.0001)  
2.3.[ADDRESS_509539] Cancer  
A 2-year, randomized, double -blind, placebo -controlled, multinational study : 
The trial enrolled women with baseline BMD T -scores between -1.0 and -2.5 at the lumbar spi[INVESTIGATOR_050], 
total hip or femoral neck, and had not experienced a fracture after age 25. A total of 252 women 
were enrolled with a median age of 59 years (Range: 35 to 84 ye ars) and either received denosumab 
60 mg (n=127) or placebo (n=125) every 6 months for a total of 4 doses along with 1000 mg 
calcium and 400 IU vitamin D daily. The primary efficacy variable was percentage change in the 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 8 of 36 07/20/21  
  BMD of the lumbar spi[INVESTIGATOR_404148] e to 1 year. The treatment differences were 5.5% [( -0.7% 
placebo, +5.5% denosumab, (95% CI 4.8, 6.3); p< 0.0001)].  
2.[ADDRESS_509540] -
transplant DXA and/or osteopenia/osteoporosis at any D XA (pre or post -transplant) . 
[ADDRESS_509541] meet the following criteria:  
1. The patient is ‚â•  [ADDRESS_509542] ant. 
3. The patient has completed a base line DXA scan ‚â§ [ADDRESS_509543] -transplant DXA scan at Day 100 ( ¬±30 days)  or up to [ADDRESS_509544] agree to use adequate contraceptive methods 
(e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should 
a woman become pregnant or suspect she is pregnant while she or her partner is 
participating in this study, she should inform her treating physician immediately.  
7. Participant must understand the investigational nature of this study and sign an Independent 
Ethics Committee/Institutional Review Board approved written informed consent form 
prior to receiving any study related procedure.  
Refer to Appendix A for the ELIGIBILITY VERIFICATION FORM: INCLUSION CRITERIA  
checklist.  
3.2 Exclusion Criteria  
Participants will be excluded from this study for the following:  
1. The patient has a history of a hypersensitivity reaction to denosumab.  
2. The patient has a h istory of osteonecrosis of the jaw.  
3. The patient has predisposing risk factors for hypocalcemia including the following:  
a. Hypoparathyroidism  
b. CrCl < 30  mL/min  
c. Dialysis  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 9 of 36 07/20/21  
  d. Malabsorption Syndrome  
4. The patient has history of any bone fracture ‚â§ 30 days prior to denosumab therapy.  
5. Pregnant or nursing female patients.  
6. The patient has clinically significant GVHD leading to hospi[INVESTIGATOR_404149].  
7. The patient has clinically significant infection leading to hospi[INVESTIGATOR_404150] (excluding hospi[INVESTIGATOR_404151], i.e., Foscarnet) per prescriber discretion.  
8. The patient is unwilling or unable to follow protocol requirements.  
9. The patien t has any condition which in the Investigator‚Äôs opi[INVESTIGATOR_404152].  
Refer to Appendix B for the ELIGIBILITY VERIFICATION FORM: EXCLUSION 
CRITERIA  checklist.  
3.3 Special Populations  
The following special populations are excluded from this study:  
‚Ä¢ Cognitively impaired adults/adults with impaired decision -making capacity  
‚Ä¢ Individuals who are not yet adults (infants, children, teenagers)  
‚Ä¢ Prisoners  
‚Ä¢ Pregnant women  
3.4 Inclusion of Women and Minorities  
Both men and women and members of all races and ethnic groups are eligible for this study.  
4 LOCAL AND STUDY -WIDE NUMBER OF SUBJECTS  
A target of 114 participants (a maximum of 150 participants and a minimum of 100  evaluable 
participants) at multiple sites, including Roswell Park, will be enrolled over a 3.6-year period  with 
enrollment to conclude by [CONTACT_58472] 2022 . 
5 LOCAL AND STUDY -WIDE RECRUITMENT METHODS  
Participants will be identified/recruited/screened from patients at the BMT clinic at Roswell Park 
and participating sites and from multi -disciplinary conference discussion.  
6 MULTI -SITE RESEARCH  
Two centers will be enrolling in this study in parallel single -center studies. The data will be jointly 
analyzed from Roswell Park Cancer Institute and the Cleveland Clinic.  
This is a multi -site study. It is the responsibility of the lead investigator to ensure that:  
‚Ä¢ All site s have the most current version of the protocol, consent document, and HIPAA 
authorization.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 10 of 36 07/20/21  
  ‚Ä¢ All required approvals (initial, continuing review and modifications) have been obtained 
at each site (including approval by [CONTACT_779]‚Äôs IRB of record).  
‚Ä¢ All modifica tions have been communicated to sites and approved (including approval by 
[CONTACT_779]‚Äôs IRB of record) before the modification is implemented.  
‚Ä¢ All engaged participating sites will safeguard data, including secure transmission of data, 
as required by [CONTACT_404162].  
‚Ä¢ All local site investigators will conduct the study in accordance with applicable federal 
regulations and local laws.  
‚Ä¢ All non -compliance with the study protocol or applicable requirements will be reported in 
accordance with loca l policy.  
Refer to: Instructions for Multi -Site Studies ( Appendix F) for additional details.  
[ADDRESS_509545] 2022 , with follow -up 
for 12 months from the start of investigational treatment. We will attempt to enroll 75 patients at 
Roswell Park and 75 patients at the Cleveland Clinic with a goal of 57 evaluable patients at each 
site for a total of 114 evaluable patient s. In the event that one site reaches that site‚Äôs expected 
accrual number goal before the other site‚Äôs goal is met, the site that has reached the site expected 
accrual may continue to enroll patients in order to contribute to the overall accrual goal.  
Patient‚Äôs participation in the study will be initiated with enrollment and last for approximately 365 
days with  completion of ‚ÄúDay 465‚Äù DXA Scan.  
Patients will be given a maximum of two (2) subcutaneous doses of denosumab [ADDRESS_509546] 2022 , and completion of data collection will take 
365 days from the final patient enrolled. We estimate preliminar y analyses will be completed 2 
years after the completion of the study accrual.  
8 STUDY ENDPOINTS  
8.1 Primary Endpoint(s)  
‚Ä¢ The primary endpoint will be BMD on ‚ÄúDay 465‚Äù DXA Scans ( Appendix E) in 
comparison to ‚ÄúDay 100‚Äù DXA scans based on the percent change in BMD (g/cm2) in the 
Total hip  and/or lumbar spi[INVESTIGATOR_404153]. Stabilization of BMD will be 
defined as a Least Significant Change (LSC) in BMD from ‚ÄúDay 100‚Äù DXA to ‚ÄúDay 465‚Äù 
DXA while improvement will be defined as any increase in BMD from ‚ÄúDay 100‚Äù DXA 
to ‚ÄúDay 465‚Äù DXA.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 11 of 36 07/20/21  
  8.2 Secondary Endpoints  
Secondary endpoints include:  
‚Ä¢ Percent change in BMD between the pre -HSCT and the Day 465 DXA scans for Total hip 
and/or lumbar spi[INVESTIGATOR_050] (L1 -L4) 
‚Ä¢ Frequency of bone fractures  
‚Ä¢ Frequency of adverse effects of denosumab (see section 17) including but not limited t o 
the following:  
o Injection/Hypersensitivity related reactions  
o Osteonecrosis of the jaw  
o Graft Versus Host Disease  
[ADDRESS_509547] and at the ‚ÄúDay +100‚Äù DXA scan must 
have decrease in BMD compared to the pre -transplant DXA scan, or have osteopenia, and/or 
osteoporosis on  either the pre -HSCT or Day +100 (up to 6 months) post-HSCT DXA scan.  
This is a Phase II multicenter, single -arm, open -label study where all patients who meet inclusion 
criteria will receive the study drug (denosumab). All patients will be followed for about [ADDRESS_509548] dose of denosumab and/or a minimum of [ADDRESS_509549] HS C infusion (Day 0). A 
total of 150 patients will be accrued. Assuming 80% complete the follow -up period, 114 patients 
should be evaluable for the primary endpoint. Patients with a Day +100 and Day +[ADDRESS_509550] one dose of denos umab, will be considered evaluable for 
response/efficacy. Response/Efficacy will be based on stabilization and/or improvement of BMD 
(defined in Section 8.1). Patients who received at least one dose of denosumab will be evaluable 
for safety.  
10 TREATMENT  
Reported adverse events (AEs) and potential risks are described in Section 13. Appropriate dose 
modifications are described in Section 10.2. 
Treatment is intended for an outpatient setting. Howeve r, at the investigator‚Äôs/physician‚Äôs 
discretion, the participant may receive treatment as an inpatient, if deemed necessary.  
10.1 Dosing and Administration  
Denosumab  
‚Ä¢ Dose: 60  mg prefilled syringe  
‚Ä¢ Administration Route: Subcutaneous Injection (See Appendix D) 
o All subjects will receive one subcutaneous (SC) injection administered in the 
subject‚Äôs upper arm, upper thigh, or abdomen by [CONTACT_404163]
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 12 of 36 07/20/[ADDRESS_509551] dosing with IP.  
o Patients are to be evaluated for hypocalcemia (corrected calcium < 8.4 mg/dL 
and/or ionized calcium < 1.19 mmol/L) prior to administration (See Appendix C)  
and this should be corrected prior to administration of denosumab.  
‚Ä¢ Frequency: Every 6 months for a maximum of 2  doses  
o Dose #1: Receive between Day [ADDRESS_509552] dose due 
to risk of hypersensitivity reactions  
o Dose #2: Receive between Day [ADDRESS_509553] 
being only commercially available as a prefilled syringe.  
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2 017/125320s181lbl.pdf  ) 
10.3 General Concomitant Medication and Supportive Care  
Participants should not be given any concomitant bone strengthening agents including 
bisphosphonates.  
Administration of calcium and vitamin D as necessary to treat or prevent hypocalcemia will be per 
the physician ‚Äôs discretion.  
10.4 Duration of Treatment  
Participants may remain on study and receive the two (2) doses of denosumab in the absence of 
disease progression, unacceptable toxicity or withdrawal from study, inter -current illn ess that 
prevents further administration of treatment, participant demonstrates an inability/refusal to 
comply with medication regime and, participant withdraws from study or as per discretion of the 
providing clinician.    
10.5 Off-Study Treatment  
At the discre tion of the treating physician, patients may continue to be  treated  with any available 
agent  once  they are off study treatment.  
11 PROCEDURES INVOLVED  
The study -specific assessments are detailed in this section and outlined in Appendix C: Schedule 
of Procedures and Observations . 
Baseline and/or Screening assessments must be performed within [ADDRESS_509554], unless otherwise indicated. Any results falling outside of the reference 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 13 of 36 07/20/21  
  ranges may be repeated at the discretion of the investigator. All on -study visit procedures are 
allowed a window of ¬±  [ADDRESS_509555] as w ell as Day 100 
¬± 30 days  (up to 6 months)  (both as part of BMT standard of care) and Day 465(¬±  60 days) post 
HSCT. These studies will include BMD (g/cm2), T-score (standard deviations), and change from 
baseline (%).  
[ADDRESS_509556] returned to acceptable or pre -study limits. The final status 
of the AE will be reported in the participant‚Äôs medical records and the appropriate eCRF.  
Reasons for treatme nt discontinuation should be classified as follows:  
‚Ä¢ Death  
‚Ä¢ Progressive disease (Per Physician Discretion)  
‚Ä¢ Toxicity:  treatment related or unrelated  
‚Ä¢ Hypersensitivity Reaction  
‚Ä¢ Osteonecrosis of the Jaw  
‚Ä¢ Any bone fracture  
‚Ä¢ Investigator judgment  
o The Investigator may discontinue a participant if, in his/her judgment, it is in the 
best interest of the participant to do so.  
‚Ä¢ Noncompliance  
‚Ä¢ Participant voluntary withdrawal  
o A participant may withdraw from the study at any time, for any reason. If a 
participa nt discontinues treatment, an attempt should be made to obtain information 
regarding the reason for withdrawal.  
‚Ä¢ Sponsor decision.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 14 of 36 07/20/[ADDRESS_509557] common adverse reactions reported for denosumab for the following indications:  
‚Ä¢ Postmenopausal osteoporo sis: Most common adverse reactions (> 5% and more common 
than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal 
pain, and cystitis. Pancreatitis has been reported in clinical trials.  
‚Ä¢ Male osteoporosis : Most common adverse r eactions (> 5% and more common than 
placebo) were: back pain, arthralgia, and nasopharyngitis.  
‚Ä¢ Bone loss due to hormone ablation for cancer : Most common adverse reactions (‚â• 10% 
and more common than placebo) were: arthralgia and back pain. Pain in extremit y and 
musculoskeletal pain have also been reported in clinical trials.  
[ADDRESS_509558] stabilization and/or improvement of bone mineral density after administration 
of denosumab. This may decrease the risk of future adverse  events associated with bone loss after 
transplantation including fractures.  
[ADDRESS_509559]  
16.1 Bone Density Status  
Bone Density Status : ‚ÄúDay  465‚Äù DXA scans [(465 days ¬±  60 days from transplantation (Day 0)] 
obtained in comparison to Day +100 ¬± 30  days (up to 6 months  from transplantation) DXA scans 
based on percent change in Bone Mineral Density in both the Total Hip  and lumbar spi[INVESTIGATOR_050] (L1 -L4). 
16.2 Other Response Parameters  
Patients will also be evaluated based on percentage change in BMD (g/cm2) from pre -HSCT to 
Day [ADDRESS_509560] include:  pregnancy, lactation, fractures, and osteonecrosis of the jaw and infusion 
reactions (study drug only).  
An AE is consi dered ‚Äúunexpected‚Äù if it is not listed in the investigator brochure or is not listed at 
the specificity or severity that has been observed.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 15 of 36 07/20/21  
  17.1.1  Diagnosis Versus Signs and Symptoms  
If known, a diagnosis should be recorded on the CRF rather than individual signs  and symptoms 
(e.g.,  record only liver failure or hepatitis rather than jaundice, asterixis, and elevated 
transaminases). However, if a constellation of signs and/or symptoms cannot be clinically 
characterized as a single diagnosis or syndrome at the time of reporting, each individual event 
should be recorded as an AE or SAE on the CRF. If a diagnosis is subsequently established, it 
should be reported as follow -up information.  
17.1.2  Adverse Events Occurring Secondary to Other Events  
In general, AEs occurring seco ndary to other events (e.g.,  cascade events or clinical sequelae) 
should be identified by [CONTACT_5252]. For example, if severe diarrhea is known to have 
resulted in dehydration, it is sufficient to record only diarrhea as an AE or SAE on the CRF.  
However, clinically significant AEs occurring secondary to an initiating event that are separated 
in time should be recorded as independent events on the CRF. For example, if a severe 
gastrointestinal hemorrhage leads to renal failure, both events should be  recorded separately on 
the CRF.  
17.1.3  Abnormal Laboratory Values  
Only clinically significant (Grade 3 -5)  laboratory abnormalities that do not predate the 1st infusion 
of the investigational agent,  that require active management will be recorded as AEs or SAEs  on 
the CRF (e.g.,  abnormalities that require study drug dose modification, discontinuation of study 
treatment, more frequent follow -up assessments, further diagnostic investigation, etc.).  
If the clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g.,  alkaline 
phosphatase and bilirubin 5  x the upper limit of normal associated with cholecystitis), only the 
diagnosis (e.g.,  cholecystitis) needs to be recorded on the Adverse Event CRF.  
If the clinically significant laboratory a bnormality is not a sign of a disease or syndrome, the 
abnormality itself should be recorded as an AE or SAE on the CRF. If the laboratory abnormality 
can be characterized by a precise clinical term, the clinical term should be recorded as the AE or 
SAE. F or example, an elevated blood potassium level of 7  mEq/L should be recorded as 
‚Äúhyperkalemia‚Äù.  
Observations of the same clinically significant laboratory abnormality from visit to visit should 
not be repeatedly recorded as AEs or SAEs on the CRF, unless th eir severity, seriousness, or 
etiology changes.  
17.1.4  Preexisting Medical Conditions (Baseline Conditions)  
A preexisting medical condition should be recorded as an AE or SAE only if the frequency, 
severity, or character of the condition worsens during the study.  When recording such events on 
an Adverse Event CRF, it is important to convey the concept that the preexisting condition has 
changed by [CONTACT_9672] (e.g.,  ‚Äúmore frequent headaches‚Äù).  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 16 of 36 07/20/21  
  17.2  Grading and Reporting Adverse Events  
17.2.1  Grading and R elationship to Drug  
The descriptions and grading scales found in the CTEP Version  5 of the NCI Common 
Terminology Criteria for Adverse Events (CTCAE) will be utilized for AE reporting. CTEP 
Version  5 of the CTCAE is identified and located at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
AEs not covered by [CONTACT_404164]  5. 
The relationship of event to study drug will be documented by [CONTACT_73951]:  
‚Ä¢ Unrelated:  The event is clearly related to other factors such as the participant‚Äôs clinical 
state, other therapeutic interventions or concomitant drugs administered to the participant.  
‚Ä¢ Unlikely:  The event is doubtfully related to investigational agent(s). The event was most 
likely related to other factors such as the participant‚Äôs clinical state, other therapeutic 
interventions, or concomitant drugs.  
‚Ä¢ Probable:  The event follows a reasonable temporal sequence from the time of drug 
administration and follows a known re sponse pattern to the study drug. The event cannot 
be reasonably explained by [CONTACT_248290]‚Äôs clinical state, therapeutic 
interventions or concomitant drugs.  
‚Ä¢ Definite:  The event follows a reasonable temporal sequence from the time o f drug 
administration, follows a known response pattern to the study drug, cannot be reasonably 
explained by [CONTACT_248290]‚Äôs condition, therapeutic interventions or 
concomitant drugs; AND occurs immediately following study drug admi nistration, 
improves upon stoppi[INVESTIGATOR_1478], or reappears on re -exposure.  
17.3 Reporting Adverse Events  
Significant AEs (grade 3 -5) which are new and considered probable or definite in relation to the 
investigational agent that are occurring between the start d ate of intervention until [ADDRESS_509561] to follow -up, the 
start of a new treatment, or until the study investigator assesses the event(s) as stable or irreversible, 
will be reported. New information will be reported after it is received.  
17.4 Serious Adverse Events  
A serious adverse event (SAE) is any adverse event (experience) that in the opi[INVESTIGATOR_404154]:  
‚Ä¢ Death.  
‚Ä¢ A life -threatening adverse event (experience). Any AE that places a participant or 
participants, in the view of the Investigator or sponsor, at immediate risk of death from the 
reaction as i t occurred. It does NOT include an AE that, had it occurred in a more severe 
form, might have caused death.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 17 of 36 07/20/21  
  ‚Ä¢ Inpatient hospi[INVESTIGATOR_1081] (for >  24 hours).  
‚Ä¢ A persistent or significant incapacity or substantial disrup tion of the ability to conduct 
normal life functions.  
‚Ä¢ A congenital anomaly or birth defect.  
‚Ä¢ Important Medical Event (IME) that, based upon medical judgment, may jeopardize the 
participant and may require medical or surgical intervention to prevent one of t he outcomes 
listed above.  
17.4.[ADDRESS_509562] be reported  as an 
Unanticipated Problem. Please refer to Section  17.7.1  for details on reporting Unanticipated 
Problems.  
17.5 Investigator Reporting: Notifying the S tudy Sponsor  
Investigators MUST report (within 1  business day upon becoming aware), to the sponsor ANY 
Serious Adverse Events that are considered probable or definite in relation to the investigational 
agent(s)/intervention.  
17.[ADDRESS_509563] to 
follow -up, the start of a new treatment, or until the study investigator assesses the event(s) as stable 
or irreversible. New information will be reported  when it is received.  
17.7 Unanticipated Problems  
An Unanticipated Problem (UP) is any incident, experience, or outcome that meets all of the 
following criteria:  
‚Ä¢ Unexpected (in terms of nature, severity, or frequency) given:  
o The research procedures that are described in the study -related documents, including 
study deviations, as well as issues related to compromise of participant privacy or 
confidentiality of data.  
o The characteristics of the participant population being studied.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 18 of 36 07/20/21  
  ‚Ä¢ Related or possibly related to  participation in the research (possibly related means there is 
a reasonable possibility that the incident, experience, or outcome may have been caused by 
[CONTACT_3459]).  
‚Ä¢ Suggests that the research places participants or others at  a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized or if in relation to an AE is deemed Serious per Section  17.3. 
17.7.1  Reporting Unanticipated Problems:  
The Reportable New Information (RNI) Form will be submitted to the CRS Quality Assurance 
(QA) Office within 1  business day of becoming aware of the Unanticipated Problem. After review , 
CRS QA Office will submit the RNI to the IRB.  
When becoming aware of new information about an Unanticipated Problem, submit the updated 
information to CRS QA Office with an updated Reportable New Information Form. The site 
Investigator or designated rese arch personnel will report all unanticipated problems to the IRB in 
accordance with their local institutional guidelines.  
17.8 [COMPANY_010] Safety Reporting  
[COMPANY_010] Adverse Event Reporting Process:  
Safety Data  Timeframe for submission to [COMPANY_010]  
Suspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]Rs)  Sent to [COMPANY_010] at time of regulatory 
submission  
Pregnancy/Lactation  Within 10 calendar days of Sponsor 
awareness  
Annual Safety Report  
(e.g., EU Clinical Trial Directive [CTD] 
DSUR , and US IND Annual Report)   
Annually  
Other Aggregate Analyses  
(any report containing safety data generated 
during the course of a study)   
Sent to [COMPANY_010] at time of regulatory 
submission (e.g., FDA, IRB)  
Final (End of Study Report, including):  
‚Ä¢ Reports of unauthorized use of a 
marketed product   
Sent to [COMPANY_010] at time of regulatory 
submission (e.g., FDA, IRB) but not later 
than 1 calendar year of study completion  
17.9 FDA Reporting  
Roswell Park is not the IND holder and therefore this section is not applicable.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 19 of 36 07/20/21  
  18 DATA MANAGEMENT AND CO NFIDENTIALITY  
18.1 Data Collection  
Full build studies are managed by [CONTACT_404165]. All electronic case report form (eCRF) data are captured for these studies.  
Data management activities are performed using a CTMS system that enables the collection, 
cleaning and viewing of clinical trial data. CRS Data Management designs the study -specific 
database and facilitates development by [CONTACT_404166]. Once the database 
design is appr oved by [CONTACT_737], Statistician, and Clinical Research Coordinator, the 
database is put into production and data entry can begin. Data can be entered and changed only by 
[CONTACT_356709].  
18.2 Maintenance of Study Documents  
Essential documents will be retained per Roswell Park‚Äôs policy for 6  years from the study 
termination date. These documents could be retained for a longer period, however, if required by 
[CONTACT_404167] R oswell Park.  
18.3 Revisions to the Protocol  
Roswell Park may make such changes to the protocol as it deems necessary for safety reasons or 
as may be required by [CONTACT_941] U.S. FDA or other regulatory agencies. Revisions will be submitted to 
the IRB/ERC for written ap proval before implementation.  
18.[ADDRESS_509564] the site will be 
identified only by a participant identification number (Participant ID, PID) to maintain 
confidentiality. All records will be kept in a limited access environment. All computer entry and 
networking programs will be done using PI[INVESTIGATOR_34107]. Information will not be released without 
written authorization of the participant.  
19 STATISTICAL PLAN  
The primary objective is to show the effectiveness of denosumab on stabilization and/or 
improvement of BMD ( defined in Section 8.1) in allogeneic HSCT patients who have experienced 
either BMD loss between baseline (pre -HSCT) and Day +100 (up to 6 months) post-HSCT, or 
who have osteopenia or osteoporosis at either the pre -BMT or Day+100 (up to 6 months) post -
HSCT DXA scan. DXA scans will be obtained at baseline (pre - HSCT), at time of enrollment (Day 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 20 of 36 07/20/21  
  +100 , (up to 6 months)  post- HSCT) and at Day +[ADDRESS_509565]. The primary endpoint will be 
the slope in bone mineral density (g/cm2) regressed on time from the time of enrollment to Day 
[ADDRESS_509566] in both Total Hip  and lumbar spi[INVESTIGATOR_050] (average of L1 -L4). 
The primary analysis for both the Total Hip and lumbar spin e will consist of a regression model 
of the percent change from enrollment to Day [ADDRESS_509567] Square (OLS) methods. 
A secondary model will include and expand upon a list of covariates to explore the effects of 
demographic, disease and treatment characteristics on BMD loss and effectiveness of denosumab 
using an a nalysis -of-covariance (ANCOVA) model. Examples of covariates to be tested are age, 
sex, corticosteroid exposure, and graft -versus -host disease. Given the assumed high degree of 
correlation between the Total Hip and lumbar spi[INVESTIGATOR_404155], both models will be 
tested at alpha=0.05 (two -sided). Residual plots and other diagnostic methods will be used to 
evaluate compliance with model assumptions and goodness of fit.  
It is assumed under the null that the historical percent change in BMD from enrollm ent in the Total 
Hip is -6.3% and for the lumbar spi[INVESTIGATOR_53553] -2.3%, which translates to testing in our regression model 
about the hypotheses ùêª0: ùõΩ1=‚àí0.063 vs ùêªùëé: ùõΩ1‚â†‚àí0.063 and ùêª0: ùõΩ1=‚àí0.023 vs ùêªùëé: ùõΩ1‚â†
‚àí0.023 for the Total Hip and lumbar spi[INVESTIGATOR_050], respectively.  
19.1 Sample Size Determination  
BMD will be reported in g/cm2. We are setting the sample size target to n= 114 evaluable subjects 
assuming a 20% drop -out rate between enrollment and Day [ADDRESS_509568] a  regression coefficient for the Total Hip different from ùõΩ1=‚àí0.[ADDRESS_509569] a regression coefficient for the lumber different from 
ùõΩ1=‚àí0.[ADDRESS_509570] deviation for th e Total Hip 
BMD percent change of 5% and a standard deviation for the lumber BMD percent change of 2.5%.  
19.2 Demographics and Baseline Characteristics  
Descriptive statistics (as appropriate: n, percent, mean, median, min and max) will be used to 
summarize demo graphic and baseline characteristics.  
19.[ADDRESS_509571] one dose of denosumab will be evaluable for 
toxicity.  
19.5 Interim Analysis and Criteria for Early Termination of the Study  
No explicit interim analyses are planned for this study.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 21 of 36 07/20/21  
  19.6 Correlative Data Analysis  
20 PROVISIONS TO MONITOR THE DATA TO ENSURE THE SAFETY OF 
SUBJECTS  
The Roswell Park Data and Safety Monitoring Committee will assess the progress of the study, 
the safety data, and critical efficacy endpoints. The DSMC will review the study and will make 
recommendations that include but not limited to: (a) continuation of  the study, (b) modifications 
to the design , (c) suspension of, or (d) termination of the study.  
[ADDRESS_509572] the site will be 
identified only by a participant identification number  (Participant ID, PID) to maintain 
confidentiality. All records will be kept in a limited access environment. All computer entry and 
networking programs will be done using PI[INVESTIGATOR_34107]. Information will not be released without 
written authorization of the par ticipant.  
[ADDRESS_509573] result of their participation in this research 
study, they will be advised to notify the Roswell Park Patient Advocate at (716) 845 -1365 or the 
Study Doctor at (716) 845 -8412.  
Medical diagnosis and treatment for the injury will be offered, and a determination will be made 
regarding appropriate billing for the diagnosis and treatment  of the injury. A financial counselor 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 22 of 36 07/20/21  
  (716 -845-3161) will be able to provide an explanation of coverage and to answer questions the 
subject may have regarding study related billing.  
The subject is not prevented from seeking to collect compensation for inju ry related to malpractice, 
fault, or blame on the part of those involved in the research.  
[ADDRESS_509574] to any economic burden.  
30 CONSENT PROCESS  
This study will not be initiated until the protocol and infor med consent document(s) have been 
reviewed and approved by a properly constituted Institutional Review Board (IRB) or Independent 
Ethics Committee (IEC). Each participant (or legal guardian) shall read, understand, and sign an 
instrument of informed consen t prior to performance of any study -specific procedure. It is the 
responsibility of the investigator to ensure that the participant is made aware of the investigational 
nature of the treatment and that informed consent is given. Consent and enrollment will  occur after 
‚ÄúDay 100‚Äù DXA is completed as this will be the main determination of eligibility of patients.  
The Investigator is responsible for the retention of the participant log and participant records; 
although personal information may be reviewed by [CONTACT_404168], that information will be 
treated as strictly confidential and will not be made publicly available. The investigator is also 
responsible for obtaining participant authorization to access medical records and other applicable 
study specific information according to Health Insurance Portability and Accountability Act 
(HIPAA) regulations (where applicable).  
This study will be conducted in compliance with all applicable laws and regulations of the state 
and/or country and institution where the p articipant is treated. The clinical trial should be 
conducted in accordance with the ethical principles embodied in the Belmont Report: Ethical 
Principles and Guidelines for the Protection of Human Subjects of Research, consistent with good 
clinical practi ce and the applicable regulatory requirements and according to the guidelines in this 
protocol, including attached appendices.  
31 PROCESS TO DOCUMENT CONSENT IN WRITING  
The Investigator (or IRB specified designee) is responsible for obtaining written consent from each 
participant in accordance with GCP guidelines using the approved informed consent form, before 
any study specific procedures (including screening procedures) ar e performed. The informed 
consent form acknowledges all information that must be given to the participant according to 
applicable GCP guidelines, including the purpose and nature of the study, the expected efficacy 
and possible side effects of the treatmen t(s), and specifying that refusal to participate will not 
influence further options for therapy. Any additional information that is applicable to the study 
must also be included. Additional national or institutionally mandated requirements for informed 
consent must also be adhered to. The participant should also be made aware that by [CONTACT_404169], processing of sensitive clinical trial data and transfer to other countries for further 
processing is allowed.  
The Investigator or designee shall prov ide a copy of the signed consent form to the participant and 
the signed original shall be maintained in the Investigator File. A copy of the signed consent form 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No. I [ZIP_CODE]  
 Page 23 of 36 07/20/[ADDRESS_509575] any further treatment options.  
32 DRUGS OR DEVICES  
32.1 Denosumab (Prolia¬Æ)  
32.2 Active Substance and Source  
Denosumab is supplied in a single -use prefilled syringe (PFS) containing 60 mg in a 1 mL solution. 
Each PFS is intended fo r single use only.  
32.3 Drug Shipment  
Denosumab will be provided by [CONTACT_404170].  
32.4 Preparation for Administration  
Denosumab needs to be visually inspected for discoloration or particulate matter as it should be a 
clear, colorless to pale yellow solution that may contain trace amounts of translucent to white 
particles. The solution should be discarded if discolored or cloudy or contains foreign particulates.  
Prior to administration denosumab may be removed from the refrigerator and brought to room 
temperature (up to 25¬∞C/77¬∞F) by [CONTACT_404171] [ADDRESS_509576] is 
securely maintained in a locked, limited -access facility and, in accordance with the applicable 
regulatory requirements.  
Store denosumab in a refrigerator at 2oC to 8oC in the origin al carton: Do not freeze . 
Prior to administration, denosumab may be allowed to reach room temperature (up to 25oC) in the 
original container. Once removed from the refrigerator, denosumab must not be exposed to 
temperatures above 25oC and must be used with in24 hours, once at room temperature. If not used 
within [ADDRESS_509577] light and heat. Avoid 
vigorous shaking of denosumab. 
Drug storage temperature will be maintained and recorded, as applicable.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 24 of 36 07/20/21  
  33 REFERENCES  
1. Copelan EA. Hematopoietic stem -cell transplantation. N Engl J Med 2006;354:[ADDRESS_509578] K, et al. Accelerated bone mineral density loss occurs with 
similar incidence and severity, but with different risk factors, after autologous versus allogeneic 
hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the 
American Society for Blood and Marrow Transplantation 2010;16:1130 -7. 
3. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? 
Journal of bone and mineral research : the official journal of the American Society for Bone and 
Mineral Res earch 2000;15:183 -7. 
4. Pundole X, Cheema HI, Petitto GS, Lopez -Olivo MA, Suarez -Almazor ME, Lu H. 
Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem 
cell transplant: a systematic review and meta -analysis. Bone marrow transplantation 
2017;52:663 -70. 
 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 25 of 36 07/20/21  
  34 APPENDICES  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 26 of 36 07/20/21  
  Appendix A ELIGIBILITY VERIFICATION FORM: INCLUSION CRITERIA  
Participant Name: (Multi -site: use participant initials):  ___________________________  
Medical Record No.: (Multi -site: use participant IDs):  _____________________________  
Title:  A Phase II, Open -Label, Multicenter Trial to Evaluate the Efficacy and Safety of 
Denosumab in Treatment of Post -Allogenic Hem atopoietic Stem Cell Transplant Bone Loss  
INCLUSION CRITERIA  
Yes No N/A All answers must be ‚ÄúYes‚Äù or ‚ÄúN/A‚Äù for participant enrollment.  Date  
   1. The patient is ‚â•  18 years.   
   2. The patient has undergone an Allogeneic  Hematopoietic Stem Cell 
Transplant.   
   3. The patient has completed a base line DXA scan ‚â§ [ADDRESS_509579] -transplant DXA scan at Day 100 
(¬± 30 days) or up to [ADDRESS_509580] agree to use adequate 
contraceptive methods (e.g., hormonal or barrier method of birth 
control; abstinence) prior to study entry. Should a woman become 
pregnant or suspect she is pregnant while she or her partner is 
partic ipating in this study, she should inform her treating physician 
immediately.   
   7. Participant must understand the investigational nature of this study 
and sign an Independent Ethics Committee/Institutional Review 
Board approved written informed consent form prior to receiving 
any study related procedure.   
Investigator Signature: ________________________________Date: ___________  
Printed Name [CONTACT_7919]: __________________________ ________________  
 
  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 27 of 36 07/20/21  
  Appendix B ELIGIBILITY VERIFICATION FORM: EXCLUSION CRITERIA  
Participant Name: (Multi -site: use participant initials):  ___________________________  
Medical Record No.: (Multi -site: use participant IDs):  _____________________________  
Title:  A Phase II, Open -Label, Multicenter Trial to Evaluate the Efficacy and Safety of 
Denosumab in Treatment of Post -Allogenic Hematopoietic Stem Cell Transplant Bone Loss  
EXCLUSION CRITERIA  
Yes No N/A All answers must be ‚ÄúNo‚Äù or ‚ÄúN/A‚Äù for participant enrollment.  Date  
   1. The patient has a history of a hypersen sitivity reaction to 
denosumab.   
   2. The patient has a history of osteonecro sis of the jaw.   
   3. The patient has predisposing risk factors for hypocalcemia 
including the following:  
a. Hypoparathyroidism  
b. CrCl < 30  mL/m in 
c. Dialysis  
d. Malabsorption Syndrome.   
   4. The patient has history of any bone fracture ‚â§ 30 days prior to 
denosumab therapy.   
   5. Pregnant or nursing female participants.   
   6. The patient has clinically significant GVHD leading to 
hospi[INVESTIGATOR_404156].   
   7. The patient has clinically significant infection leading to 
hospi[INVESTIGATOR_404157] (excluding 
hospi[INVESTIGATOR_404158] (i.e. Foscarnet)) per prescriber discretion.   
   8. The patient is unwilling or unable to follow protocol requirements.   
   9. The patient has any condition which in the Investigator‚Äôs opi[INVESTIGATOR_404159].   
Participant meets all entry criteria:     Yes   No 
If ‚ÄúNO‚Äù, do not enroll participant in study.  
Investigator Signature: ________________________________  Date: __________  
Printed Name [CONTACT_7919]: ___________________________________________  
 
 
  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 28 of 36 07/20/21  
  Appendix C Schedule of Procedures and Observations  
Evaluation  Baseline  
(Pre-Transplant 
Evaluation) Cycle 1 - 
Day 100  
(¬± 30 days)  Cycle 2 - 
Day 280  
(¬± 30 days)  End of 
Treatment:  
Day 
465(¬±  60 days)  Follow -
Up2 
Patient Consent   X    
Medical History X    X 
Pre-Existing 
Conditions  X     
Physical Examination 
(including vital signs3) X    X 
Chemistry4 X X1 X1   
ECOG Performance 
Status  X     
Dental Clearance5 X X    
DXA Scan  X X6  X  
Denosumab   X X   
Concomitant7 
Medications   X X   
Adverse Events   X X X  
Off-Study Treatment      X8 
1. Performed day of treatment prior to denosumab administration to evaluate for hypocalcemia.  
2. Follow -up safety evaluations will occur 6 months after discontinuation of study medication for evaluation of 
vertebral/femoral fractures.  
3. Vital signs: temperature, h eart rate, respi[INVESTIGATOR_697], blood pressure, body weight, and height . Height 
collected at baseline only.  
4. Chemistry (CMP): chloride, CO 2, potassium, sodium, BUN, glucose, calcium, creatinine, total protein, 
albumin, total bilirubin, alkaline phosphatase, AS T, ALT, A/G ratio, BUN/creatinine ratio, osmol (Calc), 
anion gap).  
5. The dental clearance exam is either up to [ADDRESS_509581] -transplant DXA scan ( Day 100) may be up to 6 months after transplant.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 29 of 36 07/20/21  
  7. Only pert ains to vitamin D, calcium  (as necessary to treat or prevent hypocalcemia, per physician‚Äôs‚Äô 
discretion) , any other bone strengtheners  (if so, which one (s)), or for the treatment of an adverse drug 
reaction.   See Section 10.3. 
8.  At the discretion of the treating physician, patient may continue to be treated with any available agent once 
they are off study treatment, when clinically necessary.   At the discretion of the treating physician, patient 
may continue to be treated with any  available bone strengthening agent after the end of treatment DXA Scan, 
as clinically necessary. Subsequent bone strengtheners taken during the follow -up period will be captured as 
concomitant medications.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 30 of 36 07/20/21  
  Appendix D Prefilled Syringe Instructions  
 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 31 of 36 07/20/21  
   
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 32 of 36 07/20/21  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 33 of 36 07/20/21  
  Appendix E X-Ray Bone Densitometer  
 
Intended Use  
 
The X -ray Bone Densitometer (DPX -Bravo, DPX -Duo, DPX -NT, Prodigy, iDXA) supports the 
following intended uses:  
 
Provides an estimate of bone mineral density at various anatomical sites (Spi[INVESTIGATOR_050], Total Hip , Total 
Body, and Forearm). These values can then be compared to an Adult reference population at the 
sole discretion of the physician.  
 
Provides an assessment of relative fracture risk based on the patient‚Äôs T -score value using the 
categories of fracture risk defined by [CONTACT_38375] (WHO).  
 
Provides a standardized bone density report using data from each densitometer and p hysician - 
generated assessments based on the patient‚Äôs demographics, which can assist the physician in 
communicating scan results to the patient and the patient‚Äôs referring physician  
 
Device Description  
 
Structure  
 
The X -Ray Bone Densitometer is made up of a scan arm, X -ray source assembly, and exam 
table.  
 
Product Model  
 
DPX Bravo and Duo  
 
The DPX Bravo and Duo models use pencil beam technology with a single -crystal detector and 
have a compact table design to provi de space efficiency (see images below).  
The DPX Duo and the DPX Bravo come equipped with a scan arm that swings to the side of the 
table when not in use when not in use as a densitometer and to facilitate patient loading. X -ray 
scanning is not possible un til the scan arm is locked into the scan position. A handle releases the 
scan arm interlock and allows operator to move the scan arm for patient loading. Once the 
patient is loaded on the table, the operator moves the scan arm back to scanning position and  the 
arm locks into scan position.  
 
Measurement/Reporting  
 
Bone Mineral Density (BMD) is measured using Dual -Energy X -Ray Absorptiometry (DEXA).  
 
The bone mineral density of the lumbar spi[INVESTIGATOR_050], L1 -L4, and the Total Hip total mean is measured 
in g/cm2 as well  as standard deviations within the young adult population and within the age -
matched mean. These are also compared to baseline data as a percentage change.  
  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 34 of 36 07/20/[ADDRESS_509582] INFORMATION  
All questions related to the protocol or study implementation should be directed to:  
Roswell Park Cancer Institute  
CRS Quality Assurance (QA) Network Office  
[EMAIL_7725]   
Elm and Carlton Streets  
Buffalo, [LOCATION_001] [ZIP_CODE]  
Telephone:  
Monday  - Friday; 8: 00  AM to 4: [ADDRESS_509583]  
[PHONE_2097]  
After hours, weekends, and holidays requ est the Roswell Park Investigator  
[PHONE_2099]  
2. INFORMED CONSENT  
‚Ä¢ Informed consent must be obtained by [CONTACT_9257]/designee  from any participants 
wishing to participate, prior to any procedures or treatment . 
‚Ä¢ An informed consent template is provided  by [CONTACT_404172].  
‚Ä¢ All consent changes must  be reviewed by [CONTACT_404173].  
‚Ä¢ The informed consent must be IRB approved.  
‚Ä¢ Always check that the most  up to date version of the IRB approved consent is being used.  
‚Ä¢ Within 5 business days, notify the Roswell Park CRS QA Network Office of all participant 
withdrawals or consent to limited study participation and appropriately document the 
discontinuation and  the reason(s) why.  
3. PARTICIPANT REGISTRATION  
The participant completes the Gender, Race, and Ethnicity Form and this is placed in the study 
binder.  
Roswell Park does not grant exceptions to eligibility criteria.  
Phase  [ADDRESS_509584] be emailed 
([EMAIL_7725] ) to the Roswell Park CRS QA Network Office 
within [ADDRESS_509585] and email it to the Roswell Park 
Network QA Coordinator at CRSNetwo [EMAIL_7726] . 
4. STUDY DEVIATIONS  
‚Ä¢ If a deviation has occurred to eliminate hazard, this must be reported to the Roswell Park 
Network, site IRB and any other regulatory authority involved in the study.  
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 35 of 36 07/20/21  
  ‚Ä¢ ALL study deviations will be recorded on the Study Deviation Log . 
‚Ä¢ Participants inadvertently enrolled with significant deviation(s) from the study -specified 
criteria will be removed from the study, at the discretion of the Principle Investigator.  
5. STUDY DOC UMENTATION  
‚Ä¢ Study documents must be filled out completely and correctly. Ditto marks are not allowed.  
‚Ä¢ If an entry has been documented in error put a single line through the entry and initial and 
date the change. The Roswell Park Network QA Coordinator must be able to read what has 
been deleted.  
‚Ä¢ Do NOT  use white -out, magic marker, scratch -outs.  
‚Ä¢ Do NOT  erase entries.  
‚Ä¢ Use only black ink for documentation on the accountability form and any other study 
forms.  
‚Ä¢ It is the responsibility of Roswell Park to inform the  Investigator/ institution as to when 
these documents no longer need to be retained. If, for any reason, the Investigator desires 
to no longer maintain the study records, they may be transferred to another institution, 
another investigator, or to Roswell P ark upon written agreement between the Investigator 
and Roswell Park.  
6. DRUG ACCOUNTABILITY  
Drug accountability must be strictly maintained.  
‚Ä¢ Responsibility rests solely with the Investigator but can be delegated as appropriate (e.g.,  to 
pharmacy personnel).  
‚Ä¢ A drug accountability record form (DARF) will record quantities of study drug received, 
dispensed to participants and wasted, lot number, date dispensed, participant ID number 
and initials, quantity returned, balance remaining, manufacturer, ex pi[INVESTIGATOR_320], and the 
initials of the person dispensing the medication.  
‚Ä¢ Study drug supply will only be used in accordance with the IRB approved study.  
‚Ä¢ Drug accountability forms are protocol and agent specific;  they are study source documents 
and will be u sed to verify compliance with the study.  
‚Ä¢ An inventory count must be performed with each transaction. Any discrepancies shall be 
documented and explained.  
‚Ä¢ Drug accountability forms must be stored with study related documents.  
‚Ä¢ Each medication provided for th is study and each dosage form and strength must have its 
own DARF.  
‚Ä¢ Dispensing the wrong study supply is considered a medication error . 
‚Ä¢ NEVER  replace investigational agents with commercial product.  
‚Ä¢ Do NOT  ‚Äútransfer‚Äù, ‚Äúborrow‚Äù or ‚Äúreplace‚Äù supplies between s tudies.  
7. SERIOUS ADVERSE EVENT REPORTING  
The site Investigator or designated research personnel will report all SAEs, whether related or 
unrelated to the investigational agent(s) to the IRB in accordance with their local institutional 
guidelines . The site w ill notify the Roswell Park Network QA Coordinator within 1  business day 
APPROVED RPCI IRB
9/9/2021
Roswell Park Protocol No.: I [ZIP_CODE]  
 Page 36 of 36 07/20/[ADDRESS_509586] notification using the following forms:  
‚Ä¢ Roswell Park SAE Source form  
‚Ä¢ MedWat ch 3500A  
For instructions on notifying [COMPANY_010] Please see Section 17.8. 
A complete follow -up report must be sent to the Roswell Park Network QA Coordin ator when 
new information becomes available.  
8. UNANTICIPATED PROBLEM REPORTING  
An unanticipated problem (UP) is any incident, experience, or outcome that meets all of the criteria 
in Section  17.7. 
For all adverse events occurring that are unanticipated and related or possibly related to the 
research drug, biologic or intervention, the participating physician or delegated research staff from 
each site will  notify their local IRB in accordance with their local institutional guidelines . The 
site must also notify the Roswell Park Network QA Coordinator within 1  business day of being 
made aware of the Unanticipated Problem by [CONTACT_404174].  
 
 
APPROVED RPCI IRB
9/9/2021